Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Equity Ratio (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Equity Ratio data on record, last reported at 0.92 in Q4 2025.

  • For Q4 2025, Equity Ratio rose 7.85% year-over-year to 0.92; the TTM value through Dec 2025 reached 0.92, up 7.85%, while the annual FY2025 figure was 0.92, 7.85% up from the prior year.
  • Equity Ratio reached 0.92 in Q4 2025 per AMLX's latest filing, roughly flat from 0.92 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q4 2025 and bottomed at 1.43 in Q4 2021.
  • Average Equity Ratio over 5 years is 0.72, with a median of 0.86 recorded in 2022.
  • Peak YoY movement for Equity Ratio: soared 160.79% in 2022, then decreased 12.73% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 1.43 in 2021, then skyrocketed by 160.79% to 0.87 in 2022, then dropped by 3.73% to 0.84 in 2023, then rose by 1.59% to 0.85 in 2024, then increased by 7.85% to 0.92 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.92 in Q4 2025, 0.92 in Q3 2025, and 0.86 in Q2 2025.